Literature DB >> 26405780

hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).

Francesca Maria Carozzi1, Anna Iossa, Aurora Scalisi, Mario Sideri, Karin Louise Andersson, Massimo Confortini, Annarosa Del Mistro, Giovanni Maina, Guglielmo Ronco, Patrizio Raggi, Maria Luisa Schiboni, Marco Zappa, Paolo Giorgi Rossi.   

Abstract

Compared to spontaneous screening, an organized screening programme is characterized by the presence of protocols and recommendations for all stages including follow-up. Despite the availability of well-functioning screening programmes throughout the country, the follow-up protocol after an abnormal Pap test and negative colposcopy is not clearly defined in Italy, and there is no uniformity of indications. HPV testing for oncogenic human papillomavirus (hr-HPV) has a high negative predictive value (NPV) and high positive predictive value (PPV) for CIN2+ and its employment can reduce follow-up assessments. In order to provide indications about the management of women with ASC-US+ and the follow-up of women with cytological abnormalities and negative colposcopy, a literature analysis was carried out, taking into consideration European and American guidelines and good practice recommendations from the most important scientific associations and regulatory agencies. GISCi (Italian Group for Cervical Screening) drafted recommendations for the management of women with ASC-US, L-SIL, ASC-H, AGC, and H-SIL until their return to the routine screening interval. This protocol can be applied not only in the management of abnormal Pap smears in cytology-based programmes, but also in the management of abnormal Pap test triage after HPV positive test when HPV is the primary screening test. The protocols approved within the screening programmes must have an extensive consensus among all involved professionals, including any that women might meet outside the programme.

Entities:  

Mesh:

Year:  2015        PMID: 26405780

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  6 in total

1.  Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.

Authors:  S Gori; J Battagello; D Gustinucci; C Campari; M Zorzi; H Frayle; B Passamonti; G Sartori; S Bulletti; C Fodero; E Cesarini; R Faggiano; A Del Mistro
Journal:  BJOG       Date:  2021-01-12       Impact factor: 6.531

2.  Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review.

Authors:  Fabio Bottari; Anna D Iacobone; Rita Passerini; Eleonora P Preti; Maria T Sandri; Clementina E Cocuzza; Devin S Gary; Jeffrey C Andrews
Journal:  Obstet Gynecol       Date:  2019-09       Impact factor: 7.623

3.  Vaginal Microbiota and Cytokine Microenvironment in HPV Clearance/Persistence in Women Surgically Treated for Cervical Intraepithelial Neoplasia: An Observational Prospective Study.

Authors:  Elisabetta Caselli; Maria D'Accolti; Erica Santi; Irene Soffritti; Sara Conzadori; Sante Mazzacane; Pantaleo Greco; Carlo Contini; Gloria Bonaccorsi
Journal:  Front Cell Infect Microbiol       Date:  2020-11-05       Impact factor: 5.293

4.  Leptomeningeal Carcinomatosis of a Poorly Differentiated Cervical Carcinoma Caused by Human Papillomavirus Type 18.

Authors:  Pierpaolo Zorzato; Mattia Zambon; Silvia Gori; Helena Frayle; Maria Teresa Gervasi; Annarosa Del Mistro
Journal:  Viruses       Date:  2021-02-16       Impact factor: 5.048

5.  LINE-1 hypermethylation in white blood cell DNA is associated with high-grade cervical intraepithelial neoplasia.

Authors:  Martina Barchitta; Annalisa Quattrocchi; Andrea Maugeri; Carolina Canto; Nadia La Rosa; Maria Antonietta Cantarella; Giuseppa Spampinato; Aurora Scalisi; Antonella Agodi
Journal:  BMC Cancer       Date:  2017-08-30       Impact factor: 4.430

6.  The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women.

Authors:  Heling Bao; Xiaorong Sun; Yi Zhang; Baochuan Pang; Hua Li; Liang Zhou; Fengpin Wu; Dehua Cao; Jian Wang; Bojana Turic; Linhong Wang
Journal:  Cancer Med       Date:  2020-07-22       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.